Researchers identified two germline pathogenic variants in CHEK2 that may account for a minority of men diagnosed with testicular germ cell tumors.
Christina Bennett, MS
An exploratory analysis showed that patients who received nivolumab plus ipilimumab had better patient-reported outcomes. Do the results hold up?
Results of the 2-year follow-up analysis of the pivotal KEYNOTE-024 trial were recently published in the Journal of Clinical Oncology.
The study, published in JAMA Oncology, examined whether treatment of 22 solid tumor types was associated with two therapy-related conditions.
An analysis of a large, phase III trial investigated a potential surrogate endpoint for survival outcomes in prostate cancer patients receiving ADT.
The results of the study add to the growing body of literature regarding potential biomarkers for response to immune checkpoint inhibitors.
The results, described by an expert as “very interesting” and a “a bit surprising," focused on the impact of autoimmune antibodies on anti–PD-1 therapy.
Experts weigh in on valuable findings that can be gleaned despite the fact that the phase III trial did not generate clinically meaningful results.
Investigators evaluated whether patients with pancreatic ductal adenocarcinoma benefit from adjuvant therapy after surgery if the tumor is smaller than 1 cm.
A large pooled analysis of individuals with advanced esophageal cancer showed men and women have different side effects to chemotherapy.